[ORGANIZATION]
semaglutide
Featured in 44 tracked stories · first seen
Situations
Expanding therapeutic uses and regulatory concerns for GLP-1
43 clusters · 183 sources · last updated
Latest: Semaglutide shows efficacy in treating obesity in children aged 6 to 11
Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow
GLP-1 drugs: clinical trends, safety, and market shifts
342 clusters · 1316 sources · last updated
Latest: GLP-1 medications linked to diverse health outcomes and access challenges
The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt
Novo Nordisk raises 2026 outlook on Wegovy demand
117 clusters · 557 sources · last updated
Latest: Omada Health and Novo Nordisk present new obesity treatment data
Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi
GLP-1 receptor agonist research and safety scrutiny
13 clusters · 72 sources · last updated
Latest: FDA requires GLP-1 medication warnings for rare eye condition
Research into GLP-1 receptor agonists (GLP-1 RAs) continues to expand, investigating benefits beyond glycemic control and weight loss. Potential advantages include cardiovascular protection, kidney support, reduction in
Novo Nordisk CagriSema clinical trial results
3 clusters · 13 sources · last updated
Latest: Novo Nordisk reports weight loss data for Wegovy and CagriSema
Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase
Brazil plans semaglutide integration into SUS
12 clusters · 172 sources · last updated
Latest: Anvisa regulates weight-loss medications and seizes irregular supplements
The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to
Also covered in
-
Medical research highlights links between light exposure, Semaglutide, and heart health
[HEALTH] · 6 sources ·
-
Semaglutide Trials Reveal Less Muscle Loss with Antibody Combo; Hormonal Contraception Increases Use
[HEALTH] · 2 sources ·
-
GLP‑1 weight‑loss drugs may aid addiction treatment as summer diabetes risks rise
[HEALTH] · 2 sources ·